The role of HDL-cholesterol in preventing atherosclerotic disease

European Heart Journal, Supplement

Volumn 7, Issue F, 2005, Pages

  Barter, Philip ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

Atherosclerosis; Cardiovascular risk; Dyslipidaemia; HDL cholesterol; Inflammation

Indexed keywords

ANTICOAGULANT AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ADHESION; CONFERENCE PAPER; DISEASE COURSE; FOAM CELL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; OXIDATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

EID: 32044443204     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui036     Document Type: Conference Paper

References (28)

1. World Health Organisation figures for 1999. http://www.heartstats.org (October 2004).
2. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714.
3. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-741.
4. Castelli WP, Garrison RJ, Wilson PW et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-2838.
5. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-113.
6. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997;28:83-87.
7. Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 2003;4:228-236.
8. Oram JF. HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 2003;23:720-727.
9. Barter P. Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 2004;33:393-403.
10. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:1732-1738.
11. Barter PJ, Brewer HB Jr, Chapman MJ et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-167.
12. Cockerill GW, Huehns TY, Weerasinghe A et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001;103:108-112.
13. Cockerill GW, Saklatvala J, Ridley SH et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol 1999;19:910-917.
14. Cockerill GW, Rye KA, Gamble JR et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:1987-1994.
15. Clay MA, Pyle DH, Rye KA et al. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. Atherosclerosis 2001;157:23-29.
16. Moudry R, Spycher MO, Doran JE. Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock 1997;7:175-181.
17. Nofer JR, Geigenmuller S, Gopfert C et al. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem Biophys Res Commun 2003;310:98-103.
18. Lupattelli G, Marchesi S, Lombardini R et al. Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipemia. Metabolism 2003;52:1191-1195.
19. Hernandez C, Lecube A, Barbera G et al. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Med Sci Monit 2003;9:CR114-CR119.
20. Calabresi L, Gomaraschi M, Villa B et al. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 2002;22:656-661.
21. Xia P, Vadas MA, Rye KA et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999;274:33143-33147.
22. Wadham C, Albanese N, Roberts J et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004;109:2116-2122.
23. Mackness B, Hine D, Liu Y et al. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004;318:680-683.
24. Navab M, Imes SS, Hama SY et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039-2046.
25. Han KH, Han KO, Green SR et al. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. J Lipid Res 1999;40:1053-1063.
26. Eggesbo JB, Hjermann I, Hostmark AT et al. Lipopolysaccharide-induced monocyte procoagulant activity, fibrinopeptide A, and PAI-I levels in persons with high or low levels of HDL-lipoprotein. Thromb Res 1993;70:161-171.
27. Razavian SM, Atger V, Giral P et al. Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men. Arterioscler Thromb 1994;14:361-366.
28. Halle M, Berg A, Keul J et al. Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler Thromb Vasc Biol 1996;16:144-148.